You and GolfStud are probably correct, but I might add that a significant increase in revenue (if that happens) might also help them to decide to do so. Of course if revenues rise and they wait too long to do the BB then they will be buying at higher prices.
A suggestion: Take a look at AVXL board on IHub. AVXL shareholders are waiting for that "interim step" and "good news". There the good news is a PR from CHMP in Europe, recommending approval of its Alzheimer's drug for marketing/remuneration in Europe. Should occur by Monday. Current share price= $7.09, looking for 10x that price in 2026 if CHMP recommends, EMA approves. Back to RISKYRX now again on CNBC-TV.
Market Data 
Markets 
AI
